A smiling woman in bathrobe with short blonde hair

Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With 3D Imaging and Patient-reported Outcomes

In a 12-month split-face study of 95 patients, poly-L-lactic acid injections to one side of the midface reduced wrinkle scores and increased midface volume compared with saline on the other side, with only mild, short-lived side effects and no nodules.

Ponzo M, Lombardi M, Avvedimento S, et al.. Aesthetic surgery journal, 2026.

What it means for a patient

  • PLLA prompts the body to make new collagen. Patients in this study had three sessions.
  • At 12 months, the treated side had lower wrinkle scores and more volume than the saline side.
  • No lumps (nodules or granulomas) were seen during 12 months. The authors limit this safety finding to this formulation under these study conditions.
  • The abstract does not give the volume change in milliliters.
  • The saline-treated side of each patient's face served as the comparison.

Why this paper matters

It measured PLLA volume effects with 3D imaging against a saline-treated side of the same face over 12 months. It reported no granulomas or delayed nodules in this group.

Overview

Poly-L-lactic acid (PLLA) is an injectable that restores midface volume by prompting new collagen, in place of filling with a gel. Controlled evidence measuring its volume effect is limited. The authors ran a prospective, evaluator-blinded, split-face controlled study of a Norberg Medical PLLA formulation. Patients were enrolled from July to September 2024, and follow-up was completed in September 2025.

Findings

  • 95 patients had three standardized PLLA sessions on one side of the face and saline placebo on the other.
  • Each vial held 150 mg of PLLA in spherical microparticles, mixed with 5 mL of sterile water without lidocaine.
  • Measures: Wrinkle Severity Rating Scale (WSRS), Vectra H1 3D volume (malar, zygomatic, mandibular), FACE-Q and GAIS.
  • Two blinded evaluators rated the WSRS.
  • At 12 months, WSRS fell on the PLLA side compared with baseline and with the saline side (Δ = -0.68, P < .001).
  • 3D analysis showed sustained volume gain in all midface subunits.
  • Agreement between the two evaluators: ICC = 0.91.
  • Patients with at least a 1-grade WSRS improvement: 82.1%.
  • Patient satisfaction remained high and matched the objective findings.
  • Adverse events were mild and transient. No granulomas, nodules or vascular events were recorded.

Terms

  • Poly-L-lactic acid (PLLA): a biodegradable injectable that stimulates collagen production.
  • Biostimulatory: prompting the body to build its own tissue.
  • Collagen neogenesis: formation of new collagen.
  • Split-face study: a study in which each side of the face gets a different treatment.
  • Saline placebo: salt water injected for comparison.
  • WSRS: the Wrinkle Severity Rating Scale.
  • Vectra H1: a handheld 3D camera that measures facial volume.
  • FACE-Q: a questionnaire of patient-reported outcomes for facial treatments.
  • Granuloma: a firm lump formed by the body's reaction to foreign material.
  • Intraclass correlation coefficient (ICC): a measure of agreement between raters, from 0 to 1.

More plain summaries on midface and subperiosteal lift